Todd Harris - Mar 21, 2023 Form 4 Insider Report for Tyra Biosciences, Inc. (TYRA)

Role
Chief Executive Officer, Director
Signature
/s/ Ali D. Fawaz, Attorney-in-Fact
Stock symbol
TYRA
Transactions as of
Mar 21, 2023
Transactions value $
-$264,495
Form type
4
Date filed
3/23/2023, 07:49 PM
Previous filing
Mar 17, 2023
Next filing
Mar 28, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TYRA Common Stock Options Exercise $27.9K +12.4K +0.73% $2.25* 1.71M Mar 21, 2023 Direct
transaction TYRA Common Stock Sale -$198K -12.4K -0.72% $16.00 1.7M Mar 21, 2023 Direct F1
transaction TYRA Common Stock Options Exercise $9.1K +4.04K +0.24% $2.25* 1.71M Mar 22, 2023 Direct
transaction TYRA Common Stock Sale -$64.7K -4.04K -0.24% $16.00 1.7M Mar 22, 2023 Direct F1
transaction TYRA Common Stock Options Exercise $6.3K +2.8K +0.16% $2.25* 1.7M Mar 23, 2023 Direct
transaction TYRA Common Stock Sale -$44.8K -2.8K -0.16% $16.00 1.7M Mar 23, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TYRA Stock Option (Right to Buy) Options Exercise $0 -12.4K -2.89% $0.00 417K Mar 21, 2023 Common Stock 12.4K $2.25 Direct F2
transaction TYRA Stock Option (Right to Buy) Options Exercise $0 -4.04K -0.97% $0.00 413K Mar 22, 2023 Common Stock 4.04K $2.25 Direct F2
transaction TYRA Stock Option (Right to Buy) Options Exercise $0 -2.8K -0.68% $0.00 410K Mar 23, 2023 Common Stock 2.8K $2.25 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in March 2022.
F2 1/48th of the shares subject to the option vest monthly following March 5, 2021, the vesting commencement date.